Determining the true incidence of Bone Cement Implantation Syndrome has proven challenging due to the wide range of symptoms and the lack of standardized diagnostic criteria. Recent studies have provided insight into the prevalence of BCIS, revealing alarming statistics across various arthroplasty types. A retrospective observational study conducted by Rassir et al. in 2020 found an overall incidence of BCIS at 26% among 3,294 patients undergoing cemented arthroplasties. The incidence rates varied significantly based on the type of surgery, with hip hemiarthroplasties showing a 31% incidence, total hip arthroplasties at 24%, and total knee arthroplasties at 28%. This variability can be attributed to several factors, including patient comorbidities, surgical techniques, and the specific anesthetic management employed during the procedures.
The risk of BCIS is notably higher in certain populations, particularly cancer patients. Research by Schwarzkopf et al. reported an astonishing incidence of 74% of BCIS in cancer patients undergoing cemented hip arthroplasties, which is significantly higher than in non-cancer patients. This increased incidence is often attributed to the hypercoagulable state commonly seen in cancer patients, which predisposes them to thromboembolic events. Other risk factors for BCIS may include advanced age, pre-existing cardiovascular disease, and the volume of bone cement used during the procedure. As BCIS continues to be a significant concern in orthopedic surgery, understanding these risk factors is crucial for improving patient outcomes and minimizing the incidence of this potentially life-threatening syndrome.
